{"id":"W4384938676","doi":"10.1016/j.ejca.2023.113245","title":"Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study","year":2023,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Daiichi Sankyo Europe; National Cancer Institute; Genentech; U.S. Food and Drug Administration; Ipsen; PharmaMar; Eisai; MacroGenics; Pfizer; Symphogen; Incyte; Amgen; Deciphera Pharmaceuticals; Astex Pharmaceuticals; Les Laboratories Pierre Fabre; Exelixis; Karyopharm Therapeutics; Iterion Therapeutics; Sanofi; PTC Therapeutics; GlaxoSmithKline; Bristol-Myers Squibb; Ignyta; Eli Lilly and Company; AstraZeneca; Springworks Therapeutics; Abbott Laboratories","keywords":"Tolerability; Sunitinib; Medicine; Imatinib; Open label; Oncology; Internal medicine; Adverse effect; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008185929,0.0002115063,0.000544263,0.0003086559,0.00003718579,0.00005533525,0.00009193353,0.00000928079,0.00006783466],"category_scores_gemma":[0.0004152926,0.0001335061,0.00003713528,0.0004220091,0.00006039303,0.0001702318,0.0001059477,0.0002588044,0.000006560314],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003401094,"about_ca_system_score_gemma":0.0001852385,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001923095,"about_ca_topic_score_gemma":0.0004624185,"domain_scores_codex":[0.9976943,0.0004723504,0.0007808369,0.000259372,0.0004607957,0.0003323108],"domain_scores_gemma":[0.9987693,0.0001564363,0.000334581,0.000217202,0.0002658078,0.0002566128],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02036368,0.006492501,0.8819759,0.00001812438,0.0001893777,0.008504458,0.001832732,0.000005940243,0.00001240163,1.773698e-7,0.00002694687,0.08057775],"study_design_scores_gemma":[0.103159,0.03435043,0.8607976,0.000481227,0.00009144373,0.00004124541,0.0008279934,0.00001801651,0.00002916447,0.000001734008,0.0001106296,0.00009150331],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9975461,0.0001104355,9.669139e-7,0.0003935473,0.00008674979,0.001189654,0.00001466777,0.00001160231,0.0006462502],"genre_scores_gemma":[0.9993601,0.00005286626,0.0003509263,0.00003522443,0.0000253156,0.00005712665,0.000007252345,0.00003189987,0.00007928116],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08279537,"threshold_uncertainty_score":0.5444221,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07365699301019253,"score_gpt":0.3952851022484515,"score_spread":0.321628109238259,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}